US 11,865,205 B2
Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
Georges Gaudriault, Montpellier (FR); Sylvestre Grizot, Le Crès (FR); Mark Hurtig, Ontario (CA); and Matthew Shive, Denver, CO (US)
Assigned to MEDINCELL S.A., Jacou (FR)
Filed by MEDINCELL, Jacou (FR)
Filed on Jan. 25, 2021, as Appl. No. 17/156,781.
Application 17/156,781 is a continuation of application No. 15/776,355, abandoned, previously published as PCT/IB2016/001815, filed on Nov. 16, 2016.
Claims priority of provisional application 62/255,778, filed on Nov. 16, 2015.
Prior Publication US 2021/0322302 A1, Oct. 21, 2021
Int. Cl. A61K 9/00 (2006.01); A61P 19/02 (2006.01); A61K 31/415 (2006.01); A61K 45/06 (2006.01); A61K 47/34 (2017.01)
CPC A61K 9/0024 (2013.01) [A61K 31/415 (2013.01); A61K 45/06 (2013.01); A61K 47/34 (2013.01); A61P 19/02 (2018.01)] 19 Claims
 
1. A method for morselizing a biodegradable drug delivery composition comprising at least one pharmaceutically active principle comprising:
(1) formulating a biodegradable drug composition comprising
(a) a biodegradable triblock copolymer having the formula:
PLAv-PEGw-PLAx
wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x;
(b) a biodegradable diblock copolymer having the formula:
mPEGy-PLAz
wherein y and z are the number of repeat units with y ranging from 3 to 45 and z ranging from 7 to 327, wherein the polyethylene glycol chain in the triblock and/or the diblock copolymer is 2 kDa and
wherein the ratio of the biodegradable triblock copolymer of (a) and the biodegradable diblock copolymer of (b) is 3:2 to 1:19 in said biodegradable drug composition and
(c) at least one pharmaceutically active principle;
(2) administering said formulated biodegradable drug delivery composition in at least one joint of a patient, such that it is contained within the articulating joint capsule.